Federal Awards

Aroumougame, Asaithamby, NIH-Natl Inst On Aging, Molecular Roles for Werner Syndrome Protein in Replication Fork Maintenance, $298,890; Berry, Daniel C, NIH-Natl Inst of DDK Diseases, Regulators of the Adipose Tissue Niche Control Adiposity and Metabolism, $98,440; Burgess, Shawn Christopher, NIH-Natl Inst of DDK Diseases, Factors Controlling Metabolic Flux in the Liver, $121,500; Buszczak, Michael, NIH- Natl Inst On Aging, Systematic Characterization of an Aging Stem Cell Niche, $298,890; Casey, Brian M, NIH-Natl Inst of Child Health & Human Dev, Eunice Kennedy Shriver NICHD Maternal-Fetal Medicine Units (MFMU) Network (UG1), $16,038; Castrillon, Diego H, NIH-Natl Cancer Inst, Next-Generation Mouse Models of Endometrial Cancer, $570,932; Chiang, Cheng-Ming, NIH-Natl Cancer Inst, E2-Cellular Complexes in HPV Chromatin Transcription, $356,319;

Chook, Yuh Min, NIH-Natl Inst of General Medical Sciences, Structures and Mechanisms of Nuclear Import and Export, $477,189; Conrad, Nicholas K, NIH-Natl Inst of Allergy Infectious Diseases, Mechanisms of KSHV Posttranscriptional Gene Regulation, $405,000; Corey, David Reid, NIH, Recognition of Cellular Targets by Single and Double-Stranded Nucleic Acids, $493,649; Crandall, Craig G, NIH, Exercise in Burn Survivors, $518,350; Deberardinis, Ralph J, Johns Hopkins Univ School of Medicine, Oxygen-Regulated Metabolic Homeostasis: Therapeutic Implications of Paradigm Shif, $45,018; Feranchak, Andrew Philip, NIH-Natl Inst of DDK Diseases, Mechanisms of Cholangiocyte Secretion and Bile Formation , $328,050; French, Kristin, NIH-Natl Heart, Lung and Blood Inst, Farnesoid X receptor is a Cardiac Fed-State Receptor and Suppresses Cardiac Autophagy, $56,694;

Fu, Yang-Xin, NIH-Natl Cancer Inst, Synergy of Radiation and Immunotherapy: New Approaches, $346,275; Garg, Abhimanyu, NIH-Natl Inst of DDK Diseases, Genetic and Metabolic Basis of Familial Lipodystrophies, $498,951; Gerber, David Eric, NIH-Natl Cancer Inst, UT Southwestern NCI Natl Clinical Trials Network, $700,000; Girod, Carlos E, LAM Fdn, MIDAS Clinical Study, $1,000; Graff, Jonathan Michael, NIH-Natl Inst of DDK Diseases, Adipocyte Development: Lineage Analysis and Molecular Characterization - Resubmission, $437,401; Greenberg, David E, NIH-Natl Inst of Allergy Infectious Diseases, Gene Silencing Therapeutics for Chronic Infections in Cystic Fibrosis, $360,766; Greenberg, David E, NIH-Natl Inst of Allergy Infectious Diseases, Circumventing Antibiotic Resistance with Novel Gene-Silencing Therapeutics, $443,512; Haley, Robert Ware, Johns Hopkins Univ School of Medicine, Direct Test for Neuroinflammation with Pet Scanning, $34,461;

Hall, Christiana E, Univ of Virginia, Shine (6th yr cont), $86,470; Henkemeyer, Mark J, NIH, Bidirectional Tyrosine Kinase Signaling, $455,986; Hepler, Chelsea, NIH-Natl Inst of DDK Diseases, Mural Cell Zfp423 in Control of Adipose Remodeling in Obesity, $31,846; Hibbs, Ryan Edgemon Karr, NIH-Natl Inst of Neuro Disord & Strk, 3D Structure and Mechanism of the alpha7 Nicotinic Acetylcholine Receptor, $315,214; Idris, Ahamed H, Mount Sinai School of Medicine, VOICES 4, $54,676; Journeycake, Janna Marie, Blood Center of Wisconsin, Inc, Comparative Effectiveness in Diagnosis of VWD-YR4, $2,250; Kliewer, Steven A, NIH-Natl Inst of DDK Diseases, Tissue-specific Mechanism of Action of the Metabolic Hormones FGF19 and FGF21, $313,470; Kliewer, Steven A, Yale Univ School of Medicine, FGF21, Insulin Action and Longevity, $331,929;

Konopka, Genevieve, Georgia Inst of Technology, Human Specific Brain DNA Methylation And Neuropsychiatric Diseases, $130,956; Kowalske, Karen Jean, Univ of Texas Medical Branch, Early Exercise in the Burn Intensive Care Unit - Year 3, $61,089; Li, Stephen, NIH-Natl Inst On Aging, The Role of Twist2 in Regulating Myogenesis, $31,788; Liu, Xin, NIH-Natl Inst of General Medical Sciences, Molecular Mechanisms of Promoter-Terminator Gene Looping, $279,957; McKnight, Steven Lanier, NIH-Natl Cancer Inst, Targeting Acetyl-CoA Metabolism for the Discovery of New Anti-Cancer Therapeutics, $427,816; Lum, Lawrence, NIH-Natl Cancer Inst, Chemical Disruption of Wnt-Mediated Signal Transduction (2016-17), $417,606; Mau, I-Fan T, Univ of Texas at Austin, Ultrafast Laser Phonosurgery for Biomaterial Localization in Scarred Vocal Folds, $29,032; Minassian, Berge Arakel, Univ of Kentucky Research Fdn, Genome Editing, MRNA Suppression and Chain Termination as Therapy for Lafora Epilepsy, $303,724; Nesbitt, Shawna D, Minneapolis Medical Research Fdn, ASPirin in Reducing Events in the Elderly, $104,615;

O'Donnell-Mendell, Kathryn Ann, NIH-Natl Cancer Inst, The role of PCDH7 in Lung Cancer Pathogenesis, $357,482; Orth, Kim A, NIH-Natl Inst of General Medical Sciences, Proteostasis, AMPylation and the Unfolding Protein Response (UPR), $280,665; Pawlowski, Karen Sue, Univ of Texas at Dallas, UTD Effects of Inner Hair Cell Loss, $57,681; Piskounova, Elena, NIH-Natl Cancer Inst, Identification and Functional Characterization of Metabolic Adaptations During me_Y2, $109,966; Ready, Joseph Martin, NIH-Natl Atlanta Cancer Inst, Chemical Inhibitors of 15-prostaglandin Dehydrogenase Potentiate Hematopoietic Stem Cell Transplantation, $520,706; Rosen, Michael K, NIH-Natl Inst of General Medical Sciences, Structural Study of GTPase Regulators and Effectors, $311,647; Satterthwaite, Anne Bristol, NIH-Natl Inst of Allergy Infectious Diseases, Regulation and Consequences of Ets1 Downregulation in B Cells, $524,144; Self, David W, Mount Sinai School of Medicine, Molecular Neurobiology of Drug Addiction, $64,345; Sorrelle, Noah Bruce, NIH-Natl Cancer Inst, Pleiotrophin Promotes a Pro-Tumor and Pro-Metastatic Phenotype - Resubmission - 1, $31,448;

Takahashi, Masaya, NIH, Avance III HD (AV3) Console, $600,000; Trivedi, Jaya R, Univ of Miami, CREATE YR2, $1; Lum, Lawrence, NIH-Natl Cancer Inst, Targeting Vismodegib-Resistant Tumors Using BH3 Mimetics, $312,287; Welf, Erik, NIH-Natl Cancer Inst, Career Award for Eric Welf - Mechanisms of Melanoma Migration and Survival in 3D Microenvironments, $117,720; Whitehurst, Angelique Wright, NIH-Natl Cancer Inst, Framing Therapeutic Opportunities in Tumor-Activated Gametogenic Programs, $333,517; Xiao, Guanghua, Univ of Florida, Equivalent Partial Correlation Methods for Integrative Genetic Network Analysis, $66,217; Yuan, Wen-Cheng Stacy, NIH-Natl Cancer Inst, L-type Calcium Channels as Potential Therapeutic Targets for Melanoma, $31,677; Zia, Ayesha Noor, NIH-Natl Heart, Lung and Blood Inst, Predicting and Preventing Poor Outcomes of Venous Thromboembolism in Children, $184,127.

Nonfederal Awards

Chiang, Cheng-Ming, Cancer Prevention & Research Inst of Texas, RP140367 Targeting BRD4 in Breast Cancer, $300,000; Gao, Jinming, Cancer Prevention & Research Inst of Texas, RP140140: Turn ON the Tumor Contrast for Surgical Resection of Head and Neck Cancer, $300,000; Jamshed, Namirah, Practice Change Leaders for Aging & Health, Care of the Vulnerable Elderly (COVE), $45,000; Madabhushi, Ram, Cancer Prevention & Research Inst of Texas, Nomination of Ram Madabhushi, Ph.D. for a CPRIT First-Time, Tenure, $651,628; Malladi, Srinivas, Cancer Prevention & Research Inst of Texas, Recruitment of First-Time, Tenure-Track Faculty Members, $414,282;

Piper, Hannah Grace, Amer Society for Parenteral & Enteral Nutrition, Targeted Probiotic Therapy to Improve the Gut Microbiota in Children with Short Bowel Syndrome, $25,000; Powell, Craig M, Phelan-McDermid Syndrome Fdn, Mapping the Phenotype in Adults with PMS, $7,000; Raj, Ganesh, Univ of Texas, San Antonio, ESR1 Coregulator Binding Site Inhibitors (ECBIs) as Novel Therapeutics to Target - Year 3 Continuation, $263,158; Sathe, Meghana Nitin, Dartmouth College, Virtual Improvement Program Fundamentals 2 (VIP-F2) - Sathe, $1,350; White, Stormi Pulver, Autism Speaks, Lego Lovers: A Social Group for Children with ASD, $4,938; Yu, Hongtao, Univ of Texas MD Anderson Cancer Center, DNA-Protein Crosslink Repair Pathways and Cancer Therapy - Resubmission - 1, $149,496.

Industry Sponsored Awards, dollar amounts not available

Arriaga,Yull Edwin, Genentech Inc, Study in Patients with PD-L1-Selected, High-Risk Muscle-Invasive Bladder Cancer After Cystectomy; Arriaga, Yull Edwin, Merck Sharp & Dohme Corp, Chemotherapy Trial with Subjects with Urothelial Carcinoma; Beg, Muhammad Shaalan, Nanocarrier Co, Ltd, Escalation and Expansion Trail in Patients with Advanced Solid Tumors or Squamous Non-Small Cell Lung, Biliary Tract, and Bladder Cancer; Castro, Diana Patricia, Parexel Intl, An Open-Label, Expanded Access Protocol Intended to Provide Treatment to People in the U.S. with Duchenne Muscular Dystrophy; Castro, Diana Patricia, ReveraGen BioPharma Inc, A Phase II Open-Label, Multicenter Extension Study to Assess Vamorolone in Boys with Duchenne Muscular Dystrophy.; Castro, Diana Patricia, ReveraGen BioPharma Inc, A Phase II Open-Label, Multicenter Extension Study to Assess Vamorolone in Boys with Duchenne Muscular Dystrophy; Collins, Robert Howard, Aeglea Biotherapeutics, A Phase 1 Dose-Escalation Study of AEB1102 (Co-ArgI-PEG) in Patients with Relapsed Leukemia; Collins, Robert Howard, Agios Pharmaceuticals, Study in Patients Newly Diagnosed Acute Myeloid Leukemia;

Diercks, Deborah, Hospital Quality Fdn, Safety of Oral Anticoagulants Registry (SOAR); Dowell, Jonathan E, Taiho Oncology Inc, A Randomized, Open-Label, Multi-Center, International Phase 2 Study with Advanced or Metastatic Non-Small Cell Lung Cancer; Frankel, Arthur E, Inventiv Health Clinical, Evaluate the Safety and Tolerability of MEDI0680 (AMP-514) in Combination with MEDI4736; Frohman, Elliot, New York Univ, Extended Interval Dosing Schedules for Natalizumab; Garg, Abhimanyu, Astrazeneca Pharmaceuticals LP, Descriptive Study of Lipodystrophy; Gerber, David Eric, South Plains Oncology Consortium, Trial for Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC); Gerber, David Eric, South Plains Oncology Consortium, Trial For Patients with Relapsed Malignancies;

Girod, Carlos E, LAM Fdn, Multicenter International Durability and Safety of Sirolimus in LAM Trial; Gul, Fatma, Ipsen Pharma SAS, Assess the Effect on Voluntary Movements of AbobotulinumtoxinA 1500 Administered in Both Upper and Lower Limbs; Iannaccone, Susan Theresa, Fibrogen Inc, Trial of FG-3019, a Monoclonal Antibody to Connective Tissue Growth Factor; Iannaccone, Susan Theresa, Pfizer Inc, Placebo-Controlled of PF-06252616 in Ambulatory Boys with Duchenne Muscular Dystrophy; Klesse, Laura Jean, Novartis Pharmaceuticals Corp, Compassionate Use of Trametinib in Low Grade Glioma; Kutz Jr., Joe Walter, Otonomy Inc, Study of OTO-104 Given at 3-Month Intervals by Intratympanic Injection in Subjects with Unilateral Meniere's Disease; Lee, Kenneth H, Grace Medical Inc, Tympanoseal Research; Levine, Benjamin David, NIH-Natl Inst on Aging, Determinants of Chronotropic Incompetence in Patients with Heart Failure and a Preserved Ejection Fraction; Lingvay, Ildiko, Novo Nordisk Inc, A Trial Comparison for Subjects with type 2 Diabetes Mellitus;

Miller, David Scott, Pfizer Inc, Study in Patients with Previously Untreated Epithelial Ovarian Cancer; Neeland, Ian Jason, Novo Nordisk A/S, Impact of Liraglutide 3.0 on Body Fat Distribution; Patel, Toral R, Medicenna Therapeutics Inc, Study in Adults with Glioblastoma at First Recurrence of Progression; Roehrborn, Claus, Astellas Pharma Global Development Inc, Placebo-Controlled Study for Lower Urinary Tract Symptoms; Seikaly, Mouin Gerios, Vifor Fresenius Medical Care Renal Pharm, Study in Patients with Hyperphosphatemia; Szmuk, Peter, Masimo Corp, Oxygen Reserve Index: Utility as Early Warning for Desaturation and Clinical Laboratory Correlations in Anesthetized, Intubated, Ventilated Pediatric Patients; Verma, Udit, Emd Serono Research & Development Inst, Trial for Locally Advanced or Metastatic, Adenocarcinoma of the Stomach; Zhang, Chengcheng, Immune-Onc Therapeutics Inc, Inhibitory Leukocyte Immunoglobulin-Like Receptors.